Qiming, Hillhouse bet on Jacobio's nascent pipeline of first-in-class drug hopefuls in $55M round
Qiming Capital and Hillhouse Capital are betting on a Chinese biotech to deliver world-class innovation in their latest investment.
Aside from the two prominent VCs, Jacobio has also attracted Hong Kong-based Prudence Investment Management in the $55 million Series C.
While many of China’s more well-known biotechs have a mix of licensed and in-house products in their pipeline, Beijing-based Jacobio firmly positioned itself in novel drug R&D, setting up a subsidiary and a joint venture to fully flesh out its treatments for cancer, autoimmune and infectious diseases.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.